Method for detecting protein containing histidine buffer solution by capillary gel electrophoresis
By using IAA instead of IAM as an alkylation reagent in CE-SDS analysis, the fragment peak problem caused by the reaction of IAM and histidine in protein analysis in histidine buffer was solved, and a more accurate detection of protein drug purity was achieved. Improves the reliability and accuracy of the analysis.
Patent Information
- Application Number
- CN202411365426.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-11-19
AI Technical Summary
When capillary electrophoresis (CE-SDS) technology is used to analyze proteins containing histidine buffer, the reaction of traditional alkylating reagent IAM with histidine leads to unexpected fragmentation peaks, affecting the accuracy of the analysis results, especially in There is a lack of effective solutions in the detection of recombinant proteins and peptides.
IAA instead of IAM as the alkylation reagent, and the CE-SDS analysis method is used to confirm the cause of the formation of fragment peaks and detect its molecular weight to avoid impurities generated by the reaction of IAM and histidine, thereby achieving more accurate protein drug purity analysis.
By using IAA as an alkylation reagent, the analysis interference caused by the reaction of IAM and histidine is avoided, the accuracy and reliability of CE-SDS analysis are improved, and the molecular weight of the fragment peak is determined to be 76.6kDa and under non-reduction conditions. Ensure the accuracy of the analysis results.
Smart Images

Figure CN118980731A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biotechnology, and in particular relates to a method for detecting proteins containing histidine buffer by using capillary gel electrophoresis. Background Art
[0002] With the rapid development of the biopharmaceutical industry, the quality control and purity analysis of protein products have become a crucial link. Among them, capillary electrophoresis (CE) technology, especially the sodium dodecyl sulfate capillary electrophoresis (CE-SDS) method combined with sodium dodecyl sulfate (SDS), has been widely used in the biopharmaceutical industry and academic laboratories due to its high resolution, high sensitivity and rapid analysis capabilities. CE-SDS can not only effectively separate different molecular size isomers of proteins, but also provide quantitative purity information. It is a key tool for evaluating the quality of protein products.
[0003] In the development of biopharmaceutical products, protein stability is an important consideration. Histidine, an amino acid with good buffering capacity under physiological conditions (pH 7.4), is widely used in protein preparations, especially in therapeutic protein preparations such as monoclonal antibodies that need to resist heat stress. The addition of histidine can significantly improve the thermal stability of proteins, thereby extending the shelf life of the product;
[0004] However, when using CE-SDS technology to analyze proteins in histidine buffer, new challenges are encountered. In the traditional sample pretreatment step, alkylating agents such as iodoacetamide (IAM) are often used to close the sulfhydryl groups in proteins to prevent abnormal fragmentation under high temperature or oxidative conditions. However, when histidine is used as a buffer component, its reaction with certain alkylating agents (such as IAM) may lead to the appearance of unexpected fragment peaks, thereby affecting the accuracy of CE-SDS analysis results.
[0005] Although the application of CE-SDS in monoclonal antibody analysis has been widely studied and optimized, its applicability to other recombinant proteins and peptides needs further verification, especially in the environment of histidine buffer. How to choose a suitable alkylation reagent to avoid analytical interference and ensure the reliability of analytical results has become an urgent problem to be solved.
[0006] Therefore, there is an urgent need for a method that can accurately and reliably detect proteins in histidine buffers while solving the analytical interference problem caused by the reaction of histidine with alkylating agents. Summary of the invention
[0007] The purpose of the present invention is to provide a method for detecting a protein containing a histidine buffer by using capillary gel electrophoresis, which can realize a CE-SDS analysis method of the protein containing the histidine buffer, that is, IAA can replace IAM as an alkylation agent for the protein containing the histidine buffer, confirm that the fragmentation peak is a small molecule impurity generated after the reaction of the alkylation agent IAM and histidine, and realize the analysis of the protein containing the histidine buffer by using CE-SDS, increase the analysis and detection approach when the buffer is histidine, find out the reason why the formation of the fragmentation peak in the CE-SDS analysis depends on the sample pretreatment, and detect that the molecular weight of the fragmentation peak is about 76.6kDa, and in the non-reducing CE-SDS analysis, IAA can be used as an alkylation agent for the protein containing the histidine buffer.
[0008] The technical solution adopted by the present invention is as follows:
[0009] A method for detecting proteins containing histidine buffer by capillary gel electrophoresis. For protein preparations containing histidine as a buffer, IAA is used instead of IAM as an alkylating agent to avoid impurity peaks generated by the reaction between IAM and histidine, thereby more accurately analyzing the purity of related protein drugs.
[0010] The experiment includes the following steps:
[0011] S1: dilute the sample to be tested with sample buffer;
[0012] S2: preparing an alkylating agent and mixing it with the diluted sample in S1;
[0013] S3: incubating the sample mixed in S2;
[0014] S4: performing capillary electrophoresis analysis on the sample after incubation in S3.
[0015] The technical effects achieved by the present invention are:
[0016] The present invention compares CE-SDS and SE-HPLC experimental data and finds that due to the obvious fragmentation peak generated in the CE-SDS sample pretreatment, it is confirmed that the fragmentation peak is generated after the reaction of the alkylating agent IAM and histidine, and the higher the histidine concentration and the longer the reaction time, the higher the fragmentation peak content.
[0017] The present invention optimizes the existing CE-SDS method, realizes the analysis of proteins containing histidine buffer by using CE-SDS, and uses CE-SDS to analyze proteins containing histidine buffer, increases the way of analysis and detection when the buffer is histidine, finds out the reason why the formation of fragment peaks in CE-SDS analysis depends on sample pretreatment, and detects that the apparent molecular weight of the fragment peak is about 76.6 kDa, and in non-reducing CE-SDS analysis, IAA can be used as an alkylation agent for proteins containing histidine buffer;
[0018] Thus, the CE-SDS analysis method of proteins containing histidine buffer is realized, that is, IAA can replace IAM as an alkylation agent for proteins containing histidine buffer. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is a schematic diagram of the results of CE analysis of HSA fusion protein X (molecular weight 85KDa) under high temperature and light conditions to generate fragmentation peaks in the present invention;
[0020] Figure 2 This is a schematic diagram of the results of CE analysis of 0.5 mg / mL HSA fusion protein X samples treated with histidine buffer and placed for different time periods in the present invention;
[0021] Figure 3 This is a schematic diagram of the results of CE analysis of the fragment peak areas generated by different protein concentrations and corresponding histidine buffers in the present invention;
[0022] Figure 4 is a CE-SDS spectrum of the HSA fusion protein X containing histidine buffer and the histidine buffer in the presence or absence of IAM in the present invention;
[0023] Figure 5 It is a schematic diagram of the CE-SDS results of HSA fusion protein X, insulin, BSA, and HSA fusion protein X in the present invention;
[0024] Figure 6 It is a schematic diagram of the CE-SDS results of different alkylating agents in the present invention. DETAILED DESCRIPTION
[0025] In order to make the purpose and advantages of the present invention more clearly understood, the present invention is specifically described below in conjunction with embodiments. It should be understood that the following text is only used to describe one or several specific embodiments of the present invention, and does not strictly limit the scope of protection of the specific claims of the present invention.
[0026] Embodiment 1:
[0027] like Figure 1-6As shown, a method for detecting proteins containing histidine buffer using capillary gel electrophoresis, for protein preparations containing histidine as a buffer, using IAA instead of IAM as an alkylating agent to avoid the impurity peaks generated by the reaction between IAM and histidine, thereby more accurately analyzing the purity of related protein drugs.
[0028] The experiment includes the following steps:
[0029] S1: dilute the sample to be tested with sample buffer;
[0030] The sample buffer is selected from a Tris-HCl buffer of pH 9.0±0.1, wherein the Tris concentration is 100 mM. This setting can provide a stable pH environment for the protein sample, which helps to improve the accuracy and repeatability of electrophoresis analysis;
[0031] The sample buffer contains sodium dodecyl sulfate, and the concentration of the sodium dodecyl sulfate is 10 mg / mL. Sodium dodecyl sulfate, as a surfactant, helps dissolve the protein sample and migrate during electrophoresis, thereby improving the efficiency and effect of the analysis;
[0032] In the diluted samples, the protein concentrations were 0.25 mg / mL and 1 mg / mL, and this setting provided an appropriate sample concentration for electrophoresis analysis, which helped to improve the sensitivity and resolution of the analysis;
[0033] S2: preparing an alkylating agent and mixing it with the diluted sample in S1;
[0034] The alkylating agent may be IAA. After the diluted sample is mixed with the alkylating agent, the final concentration of the alkylating agent is 1-20 mmol / L.
[0035] S3: incubating the diluted sample in S2;
[0036] The incubation temperature is 70°C, which provides a suitable temperature condition for the sample, helps to fully incubate the protein sample, thereby ensuring the accuracy of the analysis results, and the incubation time is 10 minutes. Through this setting, a suitable incubation time can be provided for the sample, which is neither too long to cause unnecessary sample degradation nor too short to cause insufficient sample reaction;
[0037] S4: performing capillary electrophoresis analysis on the sample after incubation in S3.
[0038] After incubation, the sample was injected at 10 kV for 20 s and then analyzed by capillary electrophoresis, which provided a suitable voltage and injection time for the sample, helped to improve the efficiency and resolution of electrophoretic separation, and thus obtained more accurate analysis results;
[0039] The present application can accurately analyze protein samples and avoids problems such as fragmentation generated when using iodoacetamide (IAM) as an alkylating agent.
[0040] Embodiment 2:
[0041] This example can reflect the comparison of CE-SDS analysis of HSA fusion protein X under different destruction conditions, as follows:
[0042] 0.5 mg / ml HSA fusion protein X control (undamaged sample), light-damaged and high-temperature damaged samples were diluted in half to 0.25 mg / ml with electrophoresis sample buffer (10 mg / mL SDS, 100 mM Tris, pH 9.0), iodoacetamide (IAM) solution was added to a final concentration of 12.5 mmol / l, incubated in a 70°C water bath for 10 minutes, and analyzed by capillary gel electrophoresis. The samples were injected at a voltage of 10 kV for 20 s, and the monitoring wavelength was 214 nm.
[0043] The results are as follows Figure 1 The samples in the phosphate buffer system did not produce fragmentation peaks under the control, light and high temperature conditions, while the samples in the histidine buffer system showed very obvious fragmentation peaks (10%-40%).
[0044] Embodiment 3:
[0045] This example can reflect the comparison of CE-SDS analysis fragment peaks under different storage times, as follows:
[0046] 0.5 mg / ml HSA fusion protein X containing histidine buffer was diluted in half to 0.25 mg / ml with electrophoresis sample buffer (10 mg / mL SDS, 100 mM Tris, pH 9.0), and iodoacetamide (IAM) solution was added to a final concentration of 12.5 mmol / l. The samples were incubated in a 70°C water bath for 10 minutes. The samples were placed on the sample plate for 0 h, 24 h and 48 h, respectively, and analyzed by capillary gel electrophoresis. The samples were injected at a voltage of 10 kV for 20 s, and the monitoring wavelength was 214 nm.
[0047] The results show that if Figure 2 , the longer the sample is placed on the sample plate, the higher the fragment peak content;
[0048] Attached Figure 2In the figure, (A) CE analysis of HSA fusion protein X samples treated with 0.5 mg / mL histidine buffer and placed for different time periods. (B) CE-SDS spectra of HSA fusion protein X samples treated with 0.5 mg / mL histidine buffer and placed for different time periods.
[0049] Embodiment 4:
[0050] This example can reflect the comparison of the CE-SDS analysis of the sugar fragment peaks at different protein concentrations, as follows:
[0051] 0.5 mg / ml of HSA fusion protein X containing histidine buffer and its histidine buffer were diluted in half to 0.25 mg / ml with electrophoresis sample buffer (10 mg / mL SDS, 100 mM Tris, pH 9.0), 5 mg / ml and 40 mg / ml of HSA fusion protein X containing histidine buffer and its histidine buffer were diluted to 1 mg / ml with electrophoresis sample buffer (10 mg / mL SDS, 100 mM Tris, pH 9.0), and the above samples were all added with iodoacetamide (IAM) solution to a final concentration of 12.5 mmol / l, incubated in a 70°C water bath for 10 minutes, and the samples were placed on the sample plate for 24 hours, and analyzed by capillary gel electrophoresis. The samples were injected at a voltage of 10 kV for 20 seconds, and the monitoring wavelength was 214 nm.
[0052] The results show that if Figure 3 The lower the protein concentration, that is, the higher the histidine concentration, the higher the fragment peak area produced; the smaller the corresponding histidine buffer dilution factor, the higher the fragment peak area produced.
[0053] Embodiment 5:
[0054] This example can reflect the comparison of CE-SDS analysis of insulin glargine under different separation voltages, as follows:
[0055] The samples were configured according to Table 1. The results showed that Figure 4 , histidine and iodoacetamide must be present in the sample to react and produce fragment peaks. And when only histidine and iodoacetamide are present, the content of the reaction product is higher than that of the histidine buffer and the protein preparation containing histidine;
[0056]
[0057] Table 1: Configuration of different samples
[0058] Embodiment 6:
[0059] This example can reflect the CE-SDS analysis fragment peak (76.6Da), as follows:
[0060] Insulin, BSA, and HSA fusion protein X were diluted to 1 mg / ml with electrophoresis sample buffer (10 mg / mL SDS, 100 mM Tris, pH 9.0), and 0.5 mg / ml HSA fusion protein X containing histidine buffer was diluted in half to 0.25 mg / ml with electrophoresis sample buffer (10 mg / mL SDS, 100 mM Tris, pH 9.0). Iodoacetamide (IAM) solution was added to the above samples to a final concentration of 12.5 mmol / l, incubated in a 70°C water bath for 10 minutes, and analyzed by capillary gel electrophoresis. The samples were injected at a voltage of 10 kV for 20 s, and the monitoring wavelength was 214 nm.
[0061] The results show that if Figure 5 The coordinate is the relative mobility (1 / peak time of the sample to be tested), and the abscissa is the logarithm of the sample molecular weight. When plotting the peaks of bovine insulin, BSA (~66.4K Da), and HSA fusion protein X (~85KDa), a good linear relationship (R 2 =0.9998), and the molecular weight of the fragment peak generated by the HSA fusion protein X solution or blank solution and IAM containing histidine buffer was calculated to be approximately 76.6 KDa;
[0062] Attached Figure 5 , (A) CE-SDS spectra of HSA fusion protein X, insulin, BAS, and HSA fusion protein X in histidine buffer. (B) Mobility-molecular weight curves of insulin, BAS, and HSA fusion protein X in CE-SDS.
[0063] Embodiment 7:
[0064] This example can reflect the comparison of different alkylating agents in CE-SDS analysis, as follows:
[0065] 0.5 mg / ml HSA fusion protein X containing histidine buffer or the corresponding histidine buffer was diluted in half to 0.25 mg / ml with electrophoresis sample buffer (10 mg / mL SDS, 100 mM Tris, pH 9.0), iodine iodoacetic acid (IAA) solution was added to a final concentration of 1-20 mmol / l, N-ethylmaleimide (NEM) solution was added to a final concentration of 5 mmol / l, and incubated in a 70°C water bath for 10 minutes. The samples treated with the three alkylating agents were placed on the sample plate for 0 h and 24 h, and capillary gel electrophoresis analysis was performed. The samples were injected at a voltage of 10 kV for 20 s, and the monitoring wavelength was 214 nm.
[0066] The results show that if Figure 6, histidine buffer will react with IAM to produce fragment peaks, and the product content increases with time. When IAA is used as an alkylating agent, fragment peaks will also be produced, but the CE analysis will produce peaks very quickly (about 15 minutes), which will not affect the analysis of proteins. When NEM is used as an alkylating agent, it produces a very large product peak with histidine buffer and is not suitable as an alkylating agent. Therefore, when histidine is used as a protein preparation buffer, IAA can be selected as an alkylating agent in the non-reducing CE-SDS method analysis process.
[0067] Attached Figure 6 , (A) CE-SDS spectra of HSA fusion protein X in 0.5 mg / mL histidine buffer and different alkylating agents (B) CE-SDS spectra of histidine buffer and different alkylating agents.
[0068] The above is only a preferred embodiment of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made without departing from the principles of the present invention, and these improvements and modifications should also be considered as the protection scope of the present invention. The structures, devices and operating methods not specifically described and explained in the present invention shall be implemented according to the conventional means in the art unless otherwise specified and limited.
Claims
1. A method for detecting proteins containing histidine buffer using capillary gel electrophoresis, It is characterized in that For protein preparations containing histidine as a buffer, IAA is used instead of IAM as an alkylation agent to avoid the impurity peaks generated by the reaction between IAM and histidine, thereby more accurately analyzing the purity of related protein drugs; The experiment includes the following steps: S1: dilute the sample to be tested with sample buffer; S2: preparing an alkylating agent and mixing it with the diluted sample in S1; S3: incubating the sample mixed in S2; S4: performing capillary electrophoresis analysis on the sample after incubation in S3.
2. The method according to claim 1, Features: The sample buffer in S1 is selected from Tris-HCl buffer with a pH of 9.0±0.
1.
3. The method according to claim 2, Features: The Tris concentration of the Tris-HCl buffer is 100 mM.
4. The method according to claim 2, Features: The sample buffer contains sodium dodecyl sulfate, and the concentration of the sodium dodecyl sulfate is 10 mg / mL.
5. The method according to claim 1, Features: In the diluted samples in S1, the protein concentrations were 0.25 mg / mL and 1 mg / mL.
6. The method according to claim 1, Features: The alkylating agent in S2 is IAA. After the diluted sample is mixed with the alkylating agent, the final concentration of the IAA alkylating agent is 1-20 mmol / L.
7. The method according to claim 1, wherein the alkylating agent in S2 is IAM or no alkylating agent IAM is added, and the analysis results of HSA fusion protein X in S1 are compared when the samples to be tested are histidine, histidine buffer, and histidine-containing buffer.
8. The method according to claim 1, Features: The incubation temperature in S3 is 70°C.
9. The method according to claim 8, Features: The incubation time was 10 minutes.
10. The method according to claim 1, Features: The sample incubated in S4 was injected at 10 kV for 20 seconds and then analyzed by capillary electrophoresis.
